medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Age-structured non-pharmaceutical interventions for optimal control of COVID-19 epidemic

Quentin Richard[a], Samuel Alizon[a], Marc Choisy[a,b,c]
Mircea T. Sofonea[a], Ramsès Djidjou-Demasse[a,*]

[a]MIVEGEC, Univ. Montpellier, IRD, CNRS, Montpellier, France

[b] Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, UK

[c] Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

[*]Author for correspondence: ramses.djidjoudemasse@ird.fr

Abstract

In an epidemic, individuals can widely differ in the way they spread the infection, for instance depending on their age or on the number of days they have been infected for. The latter allows to take into account the variation of infectiousness as a function of time since infection. In the absence of pharmaceutical interventions such as a vaccine or treatment, non-pharmaceutical interventions (*e.g.* social distancing) are of great importance to mitigate the pandemic. We propose a model with a double continuous structure by host age and time since infection. By applying optimal control theory to our age-structured model, we identify a solution minimizing deaths and costs associated with the implementation of the control strategy itself. This strategy depends on the age heterogeneity between individuals and consists in a relatively high isolation intensity over the older populations during a hundred days, followed by a steady decrease in a way that depends on the cost associated to a such control. The isolation of the younger population is weaker and occurs only if the cost associated with the control is relatively low. We show that the optimal control strategy strongly outperforms other strategies such as uniform constant control over the whole populations or over its younger fraction. These results bring new facts the debate about age-based control interventions and open promising avenues of research, for instance of age-based contact tracing.

Key words. COVID-19; Optimal control; Age-structured model; Age of infection

1 Introduction

Following its emergence in December 2019, COVID-19 has become an international public health emergency [1]. The infection is similar to that caused by influenza virus regarding clinical presentation

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

and transmission mechanism [1]. Contrary to seasonal influenza, COVID-19 has become pandemic by spreading rapidly among completely naive host populations, *i.e.* with no pre-existing immunity [2–5]. At the start of the pandemic, no pharmaceutical interventions such as vaccines or treatments were available and, based on earlier epidemics, it will take several months before their deployment. For this reason, developing non-pharmaceutical intervention strategies, such as social distancing, is of great importance to mitigate the pandemic [6].

Generally, age structure is a key determinant of such acute respiratory diseases, *e.g.* when it comes to infection severity. For example, children are considered to be responsible for most of the transmission of influenza [7], but the related hospitalization and mortality burden is largely carried by people of ages over 65 years [8, 9]. While much remains unknown about the COVID-19 epidemics, evidence to date suggests that mortality among people who have been tested positive for the coronavirus is substantially higher at older ages and near zero for young children [3, 10]. Moreover, the infectiousness of an individual has been reported to vary as a function of time since infection [11], which is known to affect epidemic spread [12–14].

Here we propose an epidemiological model for the disease stage-progression [13] structured both by the continuous age of the host population and the continuous age of infection. This formulation differs from the existing literature where only one type of structure is considered at a time [15–18], and is particularly suited to investigate an infection such as COVID-19, with strong host and infect age effects. Indeed, in addition to taking into account the host population's age structure, as well as the gradient of disease severity from mild to critical symptoms, the model readily captures the variation in infectiousness as a function of the time since infection. From a theoretical point of view, age-structured models have been proposed to investigate the spread of acute respiratory diseases [19–23]. However, in a context of acute respiratory diseases with contact patterns, very few models consider both structures as continuous variables, see for instance [18, 24].

In a context of non-pharmaceutical interventions, we adopt a modeling approach based on the optimal control theory to determine the best strategy to implement during a finite time interval. In the context of age-structured models, this approach allows one to determine the optimal strategies of age-specific social distancing taking into consideration the cost of implementing such strategies [25–29]. Here, more specifically, we look for the intevention that significantly reduces morbidity associated with COVID-19 at a minimal cost. In the same context, mathematical modeling using optimal control theory has been carried out to identify optimal strategies involving non-pharmaceutical interventions to control infectious diseases such as influenza and COVID-19 [30–33]. However, none of these models take into account the age structure of the host population or the variation of the infectiousness with the time since infection.

In Section 2, we first introduce the mathematical model. The model parameters and outputs are then defined in Section 3. In Section 4, we characterize the optimal control strategy that minimizes the number of deaths as well as the cost due to the implementation of the control strategy itself. Section 5 contains the main body of the results. We first analyse the epidemic spread without any intervention,

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

before comparing the performance of the optimal control in terms of deaths and hospitalizations for different costs of the control measure. Finally, the optimal control is compared to two other strategies using the same amount of resources to control the outbreak. The article ends by a Discussion in Section 6.

2 The age-structured model of COVID-19

2.1 Model overview

At time $t \in [0,T]$, the density of individuals of age $a \in [0,a_{max}]$ that are susceptible to the infection is denoted by $S(t,a)$. These individuals can become infected with a rate called the force of infection and denoted $\lambda(t,a)$. We assume that a fraction p of these individuals are paucisymptomatic, which means they will develop very mild to no symptoms, and enter group I_p. Note that this class can also be interpreted as the fraction of the population that will not isolate themselves during their infection. Other individuals are assumed to develop more symptomatic infections, either severe I_s with proportion $q(a)$ depending on the age a, or mild I_m with proportion $1-q(a)$.

Each of the three infected host populations are structured in time since infection, so that $I_v(t,a,i)$, $v \in \{p,s,m\}$, denotes the density at time t of individuals of age a that have been infected for a duration $i \in \mathbb{R}_+$. Upon infection, all exposed individuals are assumed to remain non-infectious during an average period i_{lat}. Next, they enter an asymptomatic period during which they are infectious. Only I_m and I_s develop significant symptoms after an average time since infection i_{sympt}, which can allow them to self-isolate to limit transmission. During their infection, individuals can recover at a rate $h_v(a,i)$ ($v \in \{p,m,s\}$) that depends on the severity of the infection and the time since infection i. Severely infected individuals of age a may also die from the infection at rate $\gamma(a,i)$.

The infection life cycle is shown in Figure 1. The total size of the host population of age a at time t is

$$N(t,a) = S(t,a) + R(t,a) + \int_0^\infty \left(I_p(t,a,i) + I_m(t,a,i) + I_s(t,a,i)\right) \mathrm{d}i. \tag{1}$$

2.2 Age-structured transmission and severity

We use two components to model the infection process. First, we define the transmission probability $\beta_v(a,i)$ ($v \in \{p,m,s\}$) for each contact between an infected of age a and a susceptible person, which depends on the time since infection i. Second, we introduce the kernel $K(a,a')$ that represents the average number of contacts by unit of time between an individual of age a' and an individual of age a. Here, this contact matrix is informed by data from an earlier study conducted in France [34]. The force of infection underwent by susceptible individuals of age a at time t is then given by

$$\lambda(t,a,c) = (1-c(t,a)) \int_0^{a_{\max}} K(a,a') \int_0^\infty \left(\beta_s(a',i) I_s(t,a',i) + \beta_m(a',i) I_m(t,a',i) + \beta_p(a',i) I_p(t,a',i)\right) \mathrm{d}i \, \mathrm{d}a'. \tag{2}$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 1: **The model flow diagram.** Susceptible hosts of age a at time t ($S(t,a)$) are exposed to the virus with a force of infection $\lambda(t,a)$. A fraction p of exposed individuals, which are infected since time i, will never develop symptoms and enter the group of paucisymptomatic infections ($I_p(t,a,i)$). The rest will develop symptomatic infections, either severe ($I_s(t,a,i)$) with proportion $q(a)$ depending on age a of individuals, or mild ($I_m(t,a,i)$). Exposed individuals remain non-infectious for a duration i_{lat} after infection. Next, they become asymptomatic infectious and only symptomatic infected will develop symptoms at time i_{sympt} after infection. Infected individuals recover at rate $h_v(a,i)$. Only severely infected of age a die from the infection at rate $\gamma(a,i)$. Notations are shown in Table 1.

Here, $c(t,a)$ is the percentage of reduction of contacts towards people with age a, due to public measures, at time t. The total force of infection at time t in the whole population is computed as $\int_0^{a_{\max}} \lambda(t,a,c)\mathrm{d}a$.

The dynamics of newly infected individuals (*i.e.* $i=0$) in each group is thus defined by

$$\begin{cases} I_s(t,a,0) &= (1-p)q(a)\lambda(t,a,c)S(t,a), \\ I_m(t,a,0) &= (1-p)(1-q(a))\lambda(t,a,c)S(t,a), \\ I_p(t,a,0) &= p\lambda(t,a,c)S(t,a). \end{cases} \tag{3}$$

We assume that only severe infections I_s lead to hospitalization and we denote by

$$H(t) = \int_0^{a_{\max}} \int_{i_{sympt}}^{\infty} I_s(t,a,i)\mathrm{d}i\ \mathrm{d}a \tag{4}$$

the total population hospitalized at time t, where i_{sympt} is the average time to symptoms onset. Each individual of age a dies at a rate $\mu(a,H(t))$ at time t, defined by

$$\mu\left(a,H(t)\right) = \mu_{nat}(a) + \mu_{add}\left(a,H(t)\right).$$

In the latter equation, μ_{nat} denotes the natural mortality rate when hospitals are not saturated. Further, we assume that this rate increases significantly as soon as the number of severe cases exceeds the healthcare capacity H_{sat} and μ_{add} is such additional death rate due to hospital saturation (see Section 3.2).

We apply the same reasoning by assuming that the disease-related mortality can increase because of hospital saturation. Therefore, severely infected individuals of age a infected since time i die at time t at rate $\gamma(a,i,H(t))$ defined by

$$\gamma(a,i,H(t)) = \left(\gamma_{dir}(a) + \gamma_{indir}(a,H(t))\right)\mathbf{1}_{[i_{sympt},i^s_{\max}]}(i).$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Here, γ_{dir} and γ_{indir} are mortality rates directly and indirectly due to the COVID-19 respectively (see Section 3.2). The disease-related mortality occurs after the emergence of symptoms and before the mean final time of infection for severe cases, *i.e.* for $i \in [i_{sympt}, i^s_{\max}]$.

Finally, infected individuals of age a infected since time i recover at rates $h_s(a,i)$, $h_m(a,i)$ and $h_p(a,i)$ for severe, mild and paucisymptomatic infections respectively.

The boundary conditions (3) are coupled with the following equations:

$$\begin{cases} \dfrac{\partial S}{\partial t}(t,a) &= -\mu(a,H(t))S(t,a) - \lambda(t,a,c)S(t,a), \\ \left(\dfrac{\partial I_s}{\partial t} + \dfrac{\partial I_s}{\partial i}\right)(t,a,i) &= -\left[\mu(a,H(t)) + \gamma(a,i,H(t)) + h_s(a,i)\right] I_s(t,a,i), \\ \left(\dfrac{\partial I_m}{\partial t} + \dfrac{\partial I_m}{\partial i}\right)(t,a,i) &= -\left[\mu(a,H(t)) + h_m(a,i)\right] I_m(t,a,i), \\ \left(\dfrac{\partial I_p}{\partial t} + \dfrac{\partial I_p}{\partial i}\right)(t,a,i) &= -\left[\mu(a,H(t)) + h_p(a,i)\right] I_p(t,a,i), \\ \dfrac{\partial R}{\partial t}(t,a) &= \displaystyle\sum_{v\in\{s,m,p\}} \int_0^\infty h_v(a,i) I_v(t,a,i)\mathrm{d}i - \mu(a,H(t))R(t,a), \end{cases} \tag{5}$$

for any $(t,a,i) \in (0,T] \times [0,a_{\max}] \times \mathbb{R}_+$, with initial conditions (at $t=0$):

$$S(0,a) = S_0(a), \quad R(0,a) = 0, \quad I_s(0,a,i) = I_{s,0}(a,i), \quad I_m(0,a,i) = I_{m,0}(a,i), \quad I_p(0,a,i) = I_{A,0}(a,i)$$

for each $(a,i) \in [0,a_{\max}] \times \mathbb{R}_+$. The initial conditions of infected populations are detailed in Section 3.3. Using (3) and an integration over i of (5), one may observe that the total population N defined by (1) is strictly decreasing since it satisfies the following inequality:

$$\frac{\partial N}{\partial t}(t,a) \leq -\mu_{nat}(a)N(t,a), \quad \forall a \in [0,a_{\max}], \quad \forall t \geq 0.$$

This is due to the fact that population aging and births are neglected in this model since we consider a time horizon of only one year. Further, basic properties of the model such as existence and positiveness of solutions is out of the primary scoop of our study. However, these can be specifically addressed using an integrated semigroup approach and Volterra integral formulation (see [35–38] and references therein).

3 Epidemiological outputs, model parameters and initial conditions

In this section we briefly describe some useful epidemiological outputs, the shape of age dependent parameters considered for the simulations of model (3)-(5), and the initial conditions. All state variables and other parameters are summarized in Table 1.

3.1 Epidemiological outputs

In addition to the total number of hospitalized cases $H(t)$ at time t defined by (4), we define additional epidemiological outputs such as the number of non-hospitalized cases ($N_H(t)$), the cumulative number

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

of deaths due to COVID-19 directly ($D^{cum}_{dir}(t)$) and indirectly ($D^{cum}_{indir}(t)$) respectively by

$$N_H(t) = \int_0^{a_{\max}} \left[\int_0^{i_{sympt}} I_s(t,a,i)\mathrm{d}i + \int_0^{\infty} (I_m(t,a,i) + I_p(t,a,i))\,\mathrm{d}i \right] \mathrm{d}a, \tag{6}$$

and

$$D^{cum}_{dir}(t) = \int_0^t D_{dir}(s)\mathrm{d}s, \qquad D^{cum}_{indir}(t) = \int_0^t D_{indir}(s)\mathrm{d}s, \tag{7}$$

where $D_{dir}(t)$ and $D_{indir}(t)$ are the number of deaths at time t respectively defined by

$$D_{dir}(t) = \int_0^{a_{\max}} \int_{i_{sympt}}^{i^s_{\max}} \gamma_{dir}(a) I_s(t,a,i)\mathrm{d}i\,\mathrm{d}a,$$

$$D_{indir}(t) = \int_0^{a_{\max}} \mu_{add}(a,H(t))N(t,a)\mathrm{d}a + \int_0^{a_{\max}} \gamma_{indir}(a,H(t)) \int_{i_{sympt}}^{i^s_{\max}} I_s(t,a,i)\mathrm{d}i\,\mathrm{d}a.$$

Note that non-hospitalized cases N_H defined by (6) are composed of the paucisymptomatic, the mildly infected, and the severely infected but not yet hospitalized populations. We can also note that every output aforementioned implicitly depends on parameter c which we will omit when no confusion is possible. However, in order to compare different public health measures we will explicitly write this dependence. The relative performance between two strategies c_1 and c_2, denoted by $\Delta(c_1,c_2)$, is estimated by assessing the cumulative number of deaths in the whole population during the T days of control period with the strategy c_1 relatively to deaths with the strategy c_2. Formally we have

$$\Delta(c_1,c_2) = 1 - \frac{D^{cum}_{dir}(c_1,T) + D^{cum}_{indir}(c_1,T)}{D^{cum}_{dir}(c_2,T) + D^{cum}_{indir}(c_2,T)}.$$

Hence, a relative performance $\Delta(c_1,c_2) = 0.1$ implies that the strategy c_1 reduces the number of deaths by 10% relatively to c_2.

3.2 Setting model parameters

We assume mortality rates indirectly due to the COVID-19 to grow as the number of hospitalisations H exceeds a healthcare capacity threshold H_{sat}. The natural mortality rate increases by $\mu_{add}(a,H)$ in the whole population and by $\gamma_{indir}(a,H)$ for severely infected individuals of age a. These rates are respectively defined by logistic functions that are arbitrarily chosen as:

$$\mu_{add}(a,H(t)) = \frac{10^{-2}\,\mu_{nat}(a)}{1+99\,\exp\left(-10\left(\frac{H(t)}{H_{sat}}-1\right)\right)}, \quad \gamma_{indir}(a,H(t)) = \frac{\gamma_{dir}(a)}{1+99\,\exp\left(-10\left(\frac{H(t)}{H_{sat}}-1\right)\right)}. \tag{8}$$

This choice of functional parameters implies that

$$\mu_{add}(a,0) \approx 0, \quad \gamma_{indir}(a,0) \approx 0, \quad \mu_{add}(a,H_{sat}) = 10^{-4}\mu_{nat}(a), \quad \gamma_{indir}(a,H_{sat}) = 10^{-2}\gamma_{dir}(a)$$

so that those additional mortalities are negligible when hospitals are not saturated (Figure 2 b,c). In case of saturation, the following estimates hold:

$$\lim_{H\to\infty} \mu_{add}(a,H) = 10^{-2}\mu_{nat}(a), \qquad \lim_{H\to\infty} \gamma_{indir}(a,H) = \gamma_{dir}(a)$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 2: (a) Transmission probabilities of paucisymptomatic infections β_p, symptomatic severe β_s and mild infections β_m. (b)-(c) Mortality rates due to the healthcare system saturation, with a maximal healthcare capacity $H_{sat} = 5 \times 10^3$.

for each $a \in [0, a_{\max}]$, meaning that the natural mortality rate is only increased by 1%, while the disease-induced mortality rate γ is doubled. Indeed, according to [39], 50% of patients in critical care will die in case of no saturation of hospitals. Here, we then make the assumption that this percentage will grow to 100% in case of over-saturation of hospitals.

The infectiousness of an individual aged a, which is infected since time i, is given by $\beta_v(a,i)$ ($v \in \{s,m,p\}$). Based on estimates described in [11], we assume that β_v does not depends on age a, *i.e.*, $\beta_v(a,i) = \beta_v(i)$. This assumption is only for parameterization purpose and does not impact the general formulation of the model proposed here (this is discussed later in Section 6). Next, we set $\beta_v(i) = \alpha \times \xi_v(i) \times \overline{\beta}(i)$, for $v \in \{s,m,p\}$. Here, as explained below, α is a scaling parameter obtained from the value of the basic reproduction number R_0. Parameter $\overline{\beta}$ is assumed to be identical to that reported in [11] and to follow a Weibull distribution $\overline{\beta} \sim W(3, 5.65)$. Parameters $\xi_v(i)$ are factors capturing the reduction of the transmission probability. For paucisymptomatic individuals, these are assumed to be constant ($\xi_p(i) = \xi_p$), while the reduction factor in more symptomatic infections (severe and mild) is assume to vary after symptom onset to capture admission in a healthcare facility or self-isolation at home. More precisely, we assume that

$$\xi_s(i) = \begin{cases} 1 & \text{if } i \in [0, i_{sympt}], \\ e^{-\ln(10)(i - i_{sympt})} & \text{if } i > i_{sympt} \end{cases} \quad \text{and} \quad \xi_m(i) = \begin{cases} 1 & \text{if } i \in [0, i_{sympt}], \\ e^{-\ln(2)(i - i_{sympt})} & \text{if } i > i_{sympt}. \end{cases} \tag{9}$$

These two functions are chosen arbitrarily by assuming that individuals do not isolate before symptoms onset ($i \leq i_{sympt}$), and that isolation is stronger when symptoms are more severe (Figure 2 (a)). We therefore assume that the transmission probability $\overline{\beta}$ is divided by 10 (respectively 2) every day after the average time of symptoms onset for individuals severely (resp. mildly) infected.

Finally, we assume that recover rates $h_v(a,i)$, $v \in \{s,m,p\}$, of infected individuals of age a infected since time i are independent of the age a and take the following form:

$$h_s(\cdot, i) = \mathbf{1}_{[i^s_{\max}, \infty]}(i), \quad h_m(\cdot, i) = h_p(\cdot, i) = \mathbf{1}_{[i^m_{\max}, \infty]}(i), \quad \forall i \in \mathbb{R}_+. \tag{10}$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

That is, one can recover from severe (resp. mild and paucisymptomatic) infections only after a time since infection $i^s_{\max}$ (resp. $i^m_{\max}$) corresponding to the mean duration of infection.

3.3 Initial conditions

According to the French public health agency [44], there were 130 confirmed cases of COVID-19 in France on March 1st, 2020, which we will consider as $t = 0$ in our model. Since tests in France were initially performed based on severe symptoms, we assume that all those cases are severe infections. Thus, we set $\int_{i_{sympt}}^{i^s_{\max}} \int_0^{a_{\max}} I_{s,0}(a,i)\mathrm{d}a\ \mathrm{d}i = 130$ as the initial severely infected individuals, which is assumed to be uniformly distributed with respect to the time since infection i on the interval $[0, i^s_{\max}]$. Using estimates from [44, 45] on the age distribution of hospitalised people, we derive an estimation of $I_{s,0}(a,i)$ for each $(a,i) \in [0, a_{\max}] \times \mathbb{R}_+$. Next, following the life cycle (Figure 1), we obtain an estimation of the total initial infected population by $\frac{I_{s,0}(a,i)}{(1-p)q(a)}$. From there, we deduce the initial mildly and paucisymptomatic infected populations respectively by

$$I_{m,0}(a,i) = \frac{1-q(a)}{q(a)} I_{s,0}(a,i) \quad \text{and} \quad I_{A,0}(a,i) = \frac{p}{q(a)(1-p)} I_{s,0}(a,i).$$

The initial susceptible population size S_0 comes from the French National Institute of Statistics and Economic Studies [42].

4 Optimal intervention

In this section, following well established methodology in optimal control theory [25–28, 46], we search for the optimal control effort function c^* that minimizes the objective functional $J : L^\infty(\mathbb{R}_+ \times [0, a_{\max}]) \ni c \longmapsto J(c) \in \mathbb{R}$, where

$$J(c) = D^{cum}_{dir}(c,T) + D^{cum}_{indir}(c,T) + \int_0^T \int_0^{a_{\max}} B(a)c^2(t,a)\mathrm{d}a\ \mathrm{d}t,$$

where D^{cum}_{dir}, D^{cum}_{indir} are cumulative number of deaths defined by (7) and $B(a)$ is the cost associated with the implementation of such control c for the age class a. Our aim is to find the function c^* satisfying

$$J(c^*) = \min_{c \in \mathscr{U}} J(c) \tag{11}$$

wherein the set $\mathscr{U}$ is defined by

$$\mathscr{U} = \{c \in L^\infty(\mathbb{R}_+ \times [0, a_{\max}]) : 0 \le c(\cdot,\cdot) \le c_{\max}\},$$

with $c_{\max} \le 1$ a positive constant. That is to say, the function c^* will minimize the cumulative number of deaths during T days, as long as the cost of the control strategy is not too large.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

State variables		
S	Susceptible individuals	
I_s	Severely infected individuals	
I_m	Mildly infected individuals	
I_p	Paucisymptomatic infected individuals	
R	Recovered individuals	
Model parameters		
Param.	Description (unit)	Values [source]
t, T	time and final time of simulations (days)	$t \in [0, T]$ (ad hoc)
$a, a_{\max}$	age and maximal age of individuals (years)	$a \in [0, a_{\max}]$, $a_{\max} = 100$ (ad hoc)
i	time since infection (days)	$\mathbb{R}_+$ (ad hoc)
i_{lat}	latency from exposed to asympt. (days)	4.2 [40]
i_{sympt}	average time of symptoms onset (days)	$i_{lat} + 1 = 5.2$ [39]
$i^s_{\max}$	mean final time of infection for severe cases (days)	$i_{sympt} + 20 = 25.2$ [41]
$i^m_{\max}$	mean final time of infection for mild cases (days)	$i_{sympt} + 17 = 22.2$ [41]
S_0	initial population of susceptible	[42]
μ_{nat}	natural death rate $\left(\text{days}^{-1}\right)$	[43]
μ_{add}	additional death rate $\left(\text{days}^{-1}\right)$	defined by (8)
H_{sat}	maximal healthcare capacity	5×10^3 [44]
$\beta_s, \beta_m, \beta_p$	transmission probabilities (unitless)	computed in Section 3.2
ξ_s, ξ_m, ξ_p	infectiousness reduction factors (unitless)	defined by (9) and $\xi_p = 0.1$ [11]
h_s, h_m, h_p	recovery rates per infection $\left(\text{days}^{-1}\right)$	defined by (10)
K	matrix of social contacts $\left(\text{days}^{-1}\right)$	[34]
c, $c_{\max}$	public health measure and its upper bound (unitless)	$c \in [0, c_{\max}]$, $c_{\max} = 0.95$ (assumed)
γ_{dir}	mortality rate directly due to the COVID-19 $\left(\text{days}^{-1}\right)$	[39]
γ_{indir}	mortality rate indirectly due to the COVID-19 $\left(\text{days}^{-1}\right)$	defined by (8)
p	proportion of paucisymptomatic (unitless)	variable
q	proportion of symptomatic requiring hospitalisation (unitless)	[39]
B	cost of the control measure (unitless)	variable

Table 1: Model variables and parameters

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Let (S, I_s, I_m, I_p, R) be a given solution of (3)-(5) then let λ and H be respectively defined by (2) and (4). After some computations (Appendix B), we find that the adjoint system of (5) reads as

$$\begin{pmatrix} \frac{\partial z_S}{\partial t}(t,a) \\ \frac{\partial z_R}{\partial t}(t,a) \\ \left(\frac{\partial z_{I_s}}{\partial t} + \frac{\partial z_{I_s}}{\partial i}\right)(t,a,i) \\ \left(\frac{\partial z_{I_m}}{\partial t} + \frac{\partial z_{I_m}}{\partial i}\right)(t,a,i) \\ \left(\frac{\partial z_{I_p}}{\partial t} + \frac{\partial z_{I_p}}{\partial i}\right)(t,a,i) \end{pmatrix} = \begin{pmatrix} \mu(a,H(t))z_S(t,a) - \mu_{add}(a,H(t)) \\ \mu(a,H(t))z_R(t,a) - \mu_{add}(a,H(t)) \\ (\mu(a,H(t)) + h_s(a,i))z_{I_s}(t,a,i) - \mu_{add}(a,H(t)) - \gamma(a,i,H(t))(1 - z_{I_s}(t,a,i)) \\ (\mu(a,H(t)) + h_m(a,i))z_{I_m}(t,a,i) - \mu_{add}(a,H(t)) \\ (\mu(a,H(t)) + h_p(a,i))z_{I_p}(t,a,i) - \mu_{add}(a,H(t)) \end{pmatrix}$$
$$- \begin{pmatrix} \zeta_2(t,a)\int_0^\infty \int_0^{a_{\max}} K(a,a')(\beta_s(a',i)I_s(t,a',i) + \beta_m(a',i)I_m(t,a',i) + \beta_p(a',i)I_p(t,a',i))\mathrm{d}a'\,\mathrm{d}i \\ 0 \\ \zeta_1(t,a)\mathbf{1}_{[i_{sympt},\infty)}(i) + \beta_s(a,i)\int_0^{a_{\max}} \zeta_2(t,a')S(t,a')K(a',a)\mathrm{d}a' + \zeta_3(t,a)h_s(a,i) \\ \beta_m(a,i)\int_0^{a_{\max}} \zeta_2(t,a')S(t,a')K(a',a)\mathrm{d}a' + \zeta_3(t,a)h_m(a,i) \\ \beta_p(a,i)\int_0^{a_{\max}} \zeta_2(t,a')S(t,a')K(a',a)\mathrm{d}a' + \zeta_3(t,a)h_p(a,i) \end{pmatrix} \tag{12}$$

with final conditions $z_S(T,a) = z_R(T,a) = 0$, $z_u(T,a,i) = 0$ and $\lim_{i\to\infty} z_u(t,a,i) = 0$, for any $u \in \{I_s, I_m, I_p\}$ and $(a,i) \in [0, a_{\max}] \times \mathbb{R}_+$, while ζ_k ($k \in \{1,2,3\}$) satisfy the system:

$$\begin{pmatrix} \zeta_1(t,a) \\ \zeta_2(t,a) \\ \zeta_3(t,a) \end{pmatrix} = \begin{pmatrix} \frac{\partial \mu}{\partial H}(a,H(t))(S(t,a)(1 - z_s(t,a)) + R(t,a)(1 - z_R(t,a))) \\ [1 - c(t,a)][(1-p)(q(a)z_{I_s} + (1-q(a))z_{I_m}) + pz_{I_p}](t,a,0) - (1 - c(t,a))z_S(t,a) \\ z_R(t,a) \end{pmatrix}$$
$$+ \begin{pmatrix} \int_0^\infty \frac{\partial \mu}{\partial H}(a,H(t))(I_s(t,a,i)(1 - z_{I_s}(t,a,i)) + I_m(t,a,i)(1 - z_{I_m}(t,a,i)))\mathrm{d}i \\ 0 \\ 0 \end{pmatrix}$$
$$+ \begin{pmatrix} \int_0^\infty \left(\frac{\partial \mu}{\partial H}(a,H(t))I_p(t,a,i)(1 - z_{I_p}(t,a,i) + \frac{\partial \gamma}{\partial H}(a,i,H(t))I_s(t,a,i)(1 - z_{I_s}(t,a,i))\right)\mathrm{d}i \\ 0 \\ 0 \end{pmatrix}. \tag{13}$$

Finally, the Hamiltonian $\mathscr{H}$ of (11) is given by (B.1). Then, solving $\dfrac{\partial \mathscr{H}}{\partial c} = 0$, it comes that

$$c^*(t,a) = \max(0, \min(\hat{c}(t,a), 1)), \tag{14}$$

for every $(t,a) \in [0,T] \times [0, a_{\max}]$, where

$$\hat{c}(t,a) = \frac{S(t,a)\lambda_0(t,a)\left[(1-p)(1-q(a))z_{I_m}(t,a,0) + (1-p)q(a)z_{I_s}(t,a,0) + pz_{I_p}(t,a,0)\right]}{2B(a)},$$

with λ_0 defined by (A.4).

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

We also assume that the cost $B(a)$ of the control measure over individuals aged $a \in [0, a_{\max}]$ is proportional to their density in the initial susceptible population S_0, *i.e.*

$$B(a) = \frac{B^* S_0(a)}{\int_0^{a_{\max}} S_0(u)\mathrm{d}u},$$

where $B^* \in \mathbb{R}_+$ is a variable parameter characterizing the relative cost in implementing the strategy. Additionally, one may consider the age distribution of the economic cost on the shape of the function B. For example, the economic cost can be assumed more important for the working population (*i.e.* age group $20-60$) compared to the older. Though, in absence of relevant references on this topic we stand with our primary assumption.

The state system (3)-(5) and the adjoint system (12)-(13) together with the control characterization (14) form the optimality system to be solved numerically. Since the state equations have initial conditions and the adjoint equations have final time conditions, we cannot solve the optimality system directly by only sweeping forward in time. Thus, an iterative algorithm, forward-backward sweep method, is used [47]. In other words, finding c^* numerically, involves first solving the state variables (3)-(5) forward in time, then solving the adjoint variables (12)-(13) backward in time, and then plugging the solutions for the relevant state and adjoint variables into (14), subject to bounds on the control function. Finally, the proof of the existence of such control is standard and is mostly based on the Ekeland's variational principle [48]. Therefore, existence of the optimal control to the above problem is assumed and we refer to [25] for more details.

5 Results

5.1 The basic reproduction number R_0

An explicit expression of the R_0 of model (3)-(5) is difficult to obtain in general. We show in Appendix A that it is possible to write $R_0 = \alpha \times r(U)$, where α is the scaling parameter introduced in Section 3.2, and $r(U)$ is the spectral radius of the next generation operator U defined on $L^1(0, a_{\max})$ by

$$U : L^1(0, a_{\max}) \ni v \longmapsto S_0(\cdot) \int_0^{\infty} \int_0^{a_{\max}} K(\cdot, a')\omega(a', i)v(a')\mathrm{d}a' \, \mathrm{d}i \in L^1(0, a_{\max}).$$

where S_0 is the initial susceptible population, K is the contact matrix and $\omega(a,i)$ is the infectiousness of individuals of age a infected since time i (Appendix A). We set $R_0 = 3.3$ [49, 50] and it follows that

$$\alpha = \frac{R_0}{r\left(\overline{U}\right)}.$$

Using a numerical approach, we find $r(\overline{U}) \approx 12.074$, whence $\alpha \approx 0.575$.

5.2 Typical outbreak dynamics simulated with the model

Numerical simulations are based on the reference values of the model parameters defined previously and summarized in Table 1, with $R_0 = 3.3$.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

We first use the model to describe the outbreak of the epidemics without any public health measure (*i.e.* $c \equiv 0$). The peak of the epidemics is reached approximately at day $t = 54$ for hospitalised people, and day $t = 48$ for non-hospitalised (Figure 3a). The delay between the two peaks is due to the latency time i_{sympt} for symptoms onset (Table 1). The healthcare capacity is quickly exceeded (about twenty days) and the number of deaths increases sharply from then on. At the end of the simulation ($t = 150$ days), the total number of infections (severe, mild and paucisymptomatic) is around 90.1% and varies with the age class considered (Figure 3 b). Further, in each age class the proportion of infected individuals is larger than the theoretical herd immunity threshold given by $1 - 1/R_0 \approx 69.7\%$ (Figure 3b). While people older than 70 are the less affected (in proportion), they however represent the age class with the highest cumulative number of deaths (Figure 3c). On the contrary, most of the infections that occur in the young population do not require hospitalisation (Figure 3d,e).

5.3 Effect of the optimal intervention

In this section, we investigate the interaction between the optimal intervention and the age structure of the population. We illustrate the optimal intervention strategy and their performance in terms of cumulative number of deaths for three costs of the control (relatively low $B^* = 10^2$, intermediate $B^* = 10^3$ and high $B^* = 10^4$). Overall, the optimal control particularly targets the older populations compared to the younger ones (Figure 4). If the cost B^* is relatively high, the optimal control is almost restricted to individuals above 55, with a significant reduction in deaths (Figure 4d,e). This strict lock down of older individuals lasts approximately 100 days for $B^* = 10^3$ and 10^4. The relative performance of the optimal control c^* compared to a doing nothing scenario ($\Delta(c^*, 0)$) is at least 92% (resp. 82%) when the cost is $B^* = 10^3$ (resp. 10^4). With a low cost of the control measure ($B^* = 10^2$), the optimal control significantly extends to younger populations (Figure 4 a), with a maximum reached near the 4th month of the epidemics and a steady decrease until the end of the control period. At first, the control is over people above 35 but that after 2 or 3 months the control begin to extend to people less than 35. The resulting reduction in the number of deaths is very pronounced with a relative performance $\Delta(c^*, 0)$ of at least 99%.

5.4 Comparative analysis and practicability of the optimal control

We investigated how the optimal strategy compares to other control strategies that use the same amount of 'resources' (that is the same cumulative cost). Assuming an relatively high cost $B^* = 10^3$, we investigated a uniform control strategy (denoted by c^u) either over the younger fraction of the population (Figure 5a) or over the whole population with level $c_{\max} = 0.95$ (Figure 5b). The effect of these strategy lasts about 55 days during which the epidemic is suppressed. However, once the control resources are exhausted, the epidemic reemerges (Figure 5c) and, in the end, the cumulative mortality over the time period of interest is comparable to that without any control measure (Figure 5d) and relative performance $\Delta(c^*, c^u)$, of the optimal control c^* relatively to the uniform control c^u, is approximately

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 3: **Epidemic simulated with default parameter values and no intervention with $p = 0.5$.** (a) Dynamics of epidemiological outputs over time: number of hospitalised, non hospitalised, cumulative deaths, recovered and susceptible. (b) Age distribution of the proportion of the population that have been infected before 150 days. (c) The number of cumulative deaths by age class and over time. (d)-(e) Density of hospitalised and non-hospitalised people by age class over time.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

92%. With the (longer) uniform control over the younger fraction of the population, the first epidemic peak is slightly delayed, but a second peak appears a few months later (Figure 5c). With this strategy, the cumulative mortality comparable to the one without any control measure (Figure 5d).

The optimal control is a continuous function and is then quite difficult to enforce in practice. However, we can derive step functions leading to practical implementations of the optimal control. For instance, the population is subdivided into 10-year amplitude classes and the control is updated every 3-weeks by keeping a constant amount of control during each 3-weeks period for each age-class. (Figure S1). Importantly, the constant defining the control intensity for each period is captured from the knowledge of the continuous optimal control strategy. The effect of such strategy is overall similar to the optimal control (Figure S1) with a relative performance of 91% compared to a doing nothing scenario.



Figure 4: **The optimal control strategy c^* plotted over time, age and its intensity, as well as their performance in terms of cumulative number of deaths for three costs of the control measure.** (a) relatively low $B^* = 10^2$, (b) intermediate $B^* = 10^3$, (c) high $B^* = 10^4$. (d) Number of hospitalizations. (e) Cumulative deaths per age at final time $T = 365$ days. The relative performance $\Delta(c^*, 0)$ of the optimal control c^* compared to a doing nothing scenario is at least 99% (resp. 92%, 82%) with $B^* = 10^2$ (resp. 10^3, 10^4). Here $p = 0.5$.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 5: **Comparing optimal control with uniform control.** (a) Illustration of the uniform control over the young population and (b) independently of the age. (c) Number of hospitalizations. (d) Cumulative deaths per age at final time $T = 365$ days. Here, we assume $B^* = 10^3$. Here $p = 0.5$.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

6 Discussion

Non-pharmaceutical public health interventions can be implemented either to mitigate the COVID-19 epidemic wave, and rely on natural immunisation, or to suppress the wave long enough to develop and implement a vaccine or a treatment. Here, we explicitly factor in the age heterogeneity of the host population in the identification of the optimal allocation of the control efforts.

We use optimal control theory to characterize an optimal strategy that significantly reduces the number of deaths, while being sustainable at the population level. Our formulation assume a quadratic cost for the control effort. We find that, with this strategy, the intensity of the control is always relatively high on the older fraction of the population during at least a hundred days, before decreasing more or less rapidly depending on the cost associated to the control. The control over the younger fraction of the population is weak and only occurs when the cost associated with the optimal control is relatively low and, even then, the level control only increases 2 or 3 months after that on the older fraction of the population. This late control over the younger part of the population actually mimics the results [31] where the control didn't peak right away. Intuitively, if control strategies come at a high cost for the population, it is best to focus on the age classes that are the most at risk. Conversely, if the control measures are more acceptable to the population, the optimal strategy is to aim wide in order to completely suppress the epidemic wave.

Information on the natural history of paucisymptomatic infections of COVID-19 remains relatively little-known [51, 52]. It is estimated that a proportion p of infected individuals will remain asymptomatic throughout the course of infection. However, this proportion remains largely unspecified in the literature [51, 52]. We explored effects of the proportion p on the optimal control strategy c^*. Overall, the proportion of paucisymptomatic infections have marginal effect of the optimal control strategy (Figure S2). The optimal control remains strong over the older population from the beginning of the epidemic, before progressively alleviated. The control over the younger population is weaker and occurs only if control cost itself is low. But, the level of control over its younger fraction increases when the proportion of paucisymptomatic infections decreases. Further, for high values of $B^* \in \{10^3, 10^4\}$, the shape of the optimal control does not change with the proportion p (Figure S2). Indeed, the epidemics cannot be stopped and the strategy is then to reduce mortality by protecting the population the most at risk (here the older population). However, with low value of $B^* = 10^2$, different shape of the optimal control give the same result since there is enough resources to stop the epidemics.

Given the leverage represented by school and university closure, we investigated the effect of control measures over individuals aged under 25. Our results show that NPIs targeting the younger fraction of the population are not very efficient in reducing cumulative mortality, unless they can be implemented strongly and for a relatively long period. Indeed, a control only over the younger population barely reduces the number of deaths by 3% compared to a doing nothing scenario (Figure 5a,c). Note that this result could depend on the contact matrix between ages, for which there is little date in France (here we used the one found by [34]). Furthermore, transmission probability could vary with

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

age, as discussed below.

The model proposed here is an extension of the classical models based on ordinary differential equations that tackled the issue of the optimal control of COVID-19 outbreak [30–33]. Here, the whole population is structured by age (a) and additionally by the time since infection (i) for infectious individuals, which echoes the model developed in [50] using a discrete-time formulation of the infection. With our continuous structure, we show that the number of new cases $I_N(t,a)$ at time t in individuals of age a is given by the renewal equation

$$I_N(t,a) = S_0(a) \int_0^{\infty} \int_0^{a_{\max}} K(a,a')\omega(a',i) I_N(t-i,a') \mathrm{d}a' \, \mathrm{d}i,$$

where K is the contact matrix and $\omega(a,i)$ is the infectiousness of individuals aged a which are infected since time i (Appendix A). For parameterisation purpouses, we assume that $\omega(a,i)$ is the product between the proportion of individuals of age a in the whole population and the infectiousness $\overline{\beta}(i)$ of individuals infected since time i. This is potentially a strong limitation since infectiousness $\overline{\beta}$ could depend on the age a thereby creating an additional heterogeneity in addition to that since the time since infection i. This issue can be particularly important since some studies suggest a low risk of transmission in the young population (*e.g.* [53]).

Another potential limiation is the lack of gender structure in the model formulation. Given the observed male biased in mortality during the COVID-19 pandemic, it has been suggested that males are more at risk of developing severe infections [54]. This heterogeneiry could readily be introduced in the model.

Contacts networks have an important role in transmission dynamic models. Epidemic models that determine which interventions can successfully prevent an outbreak may benefit from accounting for social structure and mixing patterns. Contacts are highly assortative with age across a given country, but regional differences in the age-specific contacts is noticeable [55]. The current model could be modified to explore epidemiological dynamics in a spatially structured population with non-homogeneous mixing, e.g. by using a meta-population model [56].

Another potential extension of the model would be to allow for the isolation of symptomatic cases and their contacts, following the method developed in [57] and applied recently to digital contact tracing [11]. Indeed, these measures strongly depend on the relative timing of infectiousness and the appearance of symptoms, and the formulation of the presented model seems suitable for that. However, this also raises technical challenges due to the double continuous structure. However, being able to identify age classes to follow in priority with contact tracing could be an asset in controling epidemic spread.

References

[1] Coronavirus Disease (COVID-19) Situation Reports;. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[2] Dorigatti I, Okell L, Cori A, Imai N, Baguelin M, Bhatia S, et al. Report 4: Severity of 2019-Novel Coronavirus (nCoV). 2020;p. 12.

[3] Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the Severity of Coronavirus Disease 2019: A Model-Based Analysis. The Lancet Infectious Diseases. 2020 Mar;0(0).

[4] Famulare M. 2019-nCoV: Preliminary Estimates of the Confirmed-Case-Fatality-Ratio and Infection-Fatality-Ratio, and Initial Pandemic Risk Assessment; 2020. https://institutefordiseasemodeling.github.io/nCoV-public/analyses/first_adjusted_mortality_estimates_and_risk_assessment/2019-nCoV-preliminary_age_and_time_adjusted_mortality_rates_and_pandemic_risk_assessment.html.

[5] Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating Clinical Severity of COVID-19 from the Transmission Dynamics in Wuhan, China. Nature Medicine. 2020 Mar;p. 1–5.

[6] Adam D. Special Report: The Simulations Driving the World's Response to COVID-19. Nature. 2020 Apr;580(7803):316–318.

[7] Brownstein JS, Kleinman KP, Mandl KD. Identifying Pediatric Age Groups for Influenza Vaccination Using a Real-Time Regional Surveillance System. American Journal of Epidemiology. 2005 Oct;162(7):686–693.

[8] McBean AM, Hebert PL. New Estimates of Influenza-Related Pneumonia and Influenza Hospitalizations among the Elderly. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2004 Jul;8(4):227–235.

[9] Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, et al. Influenza-Associated Hospitalizations in the United States. JAMA. 2004 Sep;292(11):1333–1340.

[10] Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020 Mar;.

[11] Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying SARS-CoV-2 Transmission Suggests Epidemic Control with Digital Contact Tracing. Science. 2020 Mar;.

[12] Kermack WO, McKendrick AG. A Contribution to the Mathematical Theory of Epidemics. Proc R Soc Lond A. 1927;115:700–721.

[13] Anderson RM, May RM. Infectious Diseases of Humans. Dynamics and Control. Oxford: Oxford University Press; 1991.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[14] Hethcote HW. The Mathematics of Infectious Diseases. SIAM review. 2000;42(4):599–653.

[15] McCluskey CC. Global Stability for an SEI Epidemiological Model with Continuous Age-Structure in the Exposed and Infectious Classes. Mathematical biosciences and engineering: MBE. 2012 Oct;9(4):819–841.

[16] Magal P, Webb G. Predicting the Number of Reported and Unreported Cases for the COVID-19 Epidemic in South Korea, Italy, France and Germany. medRxiv. 2020 Mar;p. 2020.03.21.20040154.

[17] Inaba H. Threshold and Stability Results for an Age-Structured Epidemic Model. Journal of Mathematical Biology. 1990 Jun;28(4):411–434.

[18] Dietz K, Schenzle D. Proportionate Mixing Models for Age-Dependent Infection Transmission. Journal of Mathematical Biology. 1985;22(1):117–120.

[19] Arguedas YN, Santana-Cibrian M, Velasco-Hernández JX. Transmission Dynamics of Acute Respiratory Diseases in a Population Structured by Age. Mathematical biosciences and engineering: MBE. 2019 Aug;16(6):7477–7493.

[20] Libin P, Moonens A, Verstraeten T, Perez-Sanjines F, Hens N, Lemey P, et al. Deep Reinforcement Learning for Large-Scale Epidemic Control. arXiv:200313676 [cs]. 2020 Mar;.

[21] Singh R, Adhikari R. Age-Structured Impact of Social Distancing on the COVID-19 Epidemic in India. arXiv:200312055 [cond-mat, q-bio]. 2020 Mar;.

[22] Eames KTD, Tilston NL, Brooks-Pollock E, Edmunds WJ. Measured Dynamic Social Contact Patterns Explain the Spread of H1N1v Influenza. PLoS Computational Biology. 2012 Mar;8(3).

[23] Shim E. Optimal Strategies of Social Distancing and Vaccination against Seasonal Influenza. Mathematical biosciences and engineering: MBE. 2013 Oct-Dec;10(5-6):1615–1634.

[24] Hoppensteadt F. An Age Dependent Epidemic Model**This Research Was Supported by the National Science Foundation under Grant No. 32996X2. Journal of the Franklin Institute. 1974 May;297(5):325–333.

[25] Djidjou Demasse R, Tewa JJ, Bowong S, Emvudu Y. Optimal Control for an Age-Structured Model for the Transmission of Hepatitis B. Journal of Mathematical Biology. 2016 Aug;73(2):305–333.

[26] Anita S. Analysis and Control of Age-Dependent Population Dynamics. Mathematical Modelling: Theory and Applications. Springer Netherlands; 2000.

[27] Barbu V, Iannelli M. Optimal Control of Population Dynamics. Journal of Optimization Theory and Applications. 1999 Jul;102(1):1–14.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[28] Fister KR, Lenhart S. Optimal Control of a Competitive System with Age-Structure. Journal of Mathematical Analysis and Applications. 2004 Mar;291(2):526–537.

[29] Ba M, Djidjou-Demasse R, Lam M, Tewa JJ. Optimal Intervention Strategies of Staged Progression HIV Infections through an Age-Structured Model with Probabilities of ART Drop Out. arXiv:191106703 [math, q-bio]. 2019 Nov;.

[30] Lin F, Muthuraman K, Lawley M. An Optimal Control Theory Approach to Non-Pharmaceutical Interventions. BMC Infectious Diseases. 2010 Feb;10(1):32.

[31] Djidjou-Demasse R, Michalakis Y, Choisy M, Sofonea MT, Alizon S. Optimal COVID-19 Epidemic Control until Vaccine Deployment. medRxiv. 2020 Apr;p. 2020.04.02.20049189.

[32] Kantner M, Koprucki T. Beyond Just "Flattening the Curve": Optimal Control of Epidemics with Purely Non-Pharmaceutical Interventions. arXiv:200409471 [physics, q-bio]. 2020 Apr;.

[33] Perkins A, Espana G. Optimal Control of the COVID-19 Pandemic with Non-Pharmaceutical Interventions. medRxiv. 2020 Apr;p. 2020.04.22.20076018.

[34] Béraud G, Kazmercziak S, Beutels P, Levy-Bruhl D, Lenne X, Mielcarek N, et al. The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases. PLOS ONE. 15 juil 2015;10(7):e0133203.

[35] Thieme HR. Semiflows Generated by Lipschitz Perturbations of Non-Densely Defined Operators. Differential and Integral Equations. 1990;3(6):1035–1066.

[36] Iannelli M. Mathematical Theory of Age-Structured Population Dynamics. Giardini editori e stampatori; 1995.

[37] Demasse RD, Ducrot A. An Age-Structured Within-Host Model for Multistrain Malaria Infections. SIAM Journal on Applied Mathematics. 2013 Jan;73(1):572–593.

[38] Magal P, Ruan S. Theory and Applications of Abstract Semilinear Cauchy Problems. Applied Mathematical Sciences. Springer International Publishing; 2018.

[39] Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of Non-Pharmaceutical Interventions (NPIs) to Reduce COVID- 19 Mortality and Healthcare Demand. 2020;p. 20.

[40] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New England Journal of Medicine. 2020 Jan;.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[41] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. The Lancet. 2020 Mar;.

[42] Estimation de La Population Au 1er Janvier 2020 | Insee;. https://www.insee.fr/fr/statistiques/1893198.

[43] Pyramide Des Âges | Insee;. https://www.insee.fr/fr/statistiques/2381472.

[44] Données hospitalières relatives à l'épidémie de COVID-19 - data.gouv.fr;. /es/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/.

[45] CDCMMWR. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morbidity and Mortality Weekly Report. 2020;69.

[46] Feichtinger G, Tragler G, Veliov VM. Optimality Conditions for Age-Structured Control Systems. Journal of Mathematical Analysis and Applications. 2003 Dec;288(1):47–68.

[47] Lenhart S, Workman JT. Optimal Control Applied to Biological Models. CRC press; 2007.

[48] Ekeland I. On the Variational Principle. Journal of Mathematical Analysis and Applications. 1974 Aug;47(2):324–353.

[49] Salje H, Kiem CT, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al.. Estimating the Burden of SARS-CoV-2 in France; 2020.

[50] Sofonea MT, Reyné B, Elie B, Djidjou-Demasse R, Selinger C, Michalakis Y, et al. Epidemiological Monitoring and Control Perspectives: Application of a Parsimonious Modelling Framework to the COVID-19 Dynamics in France. medRxiv. 2020 May;p. 2020.05.22.20110593.

[51] Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki Si, Ishihara T, et al. Natural History of Asymptomatic SARS-CoV-2 Infection. New England Journal of Medicine. 2020 Jun;0(0):null.

[52] Buitrago-Garcia DC, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. The Role of Asymptomatic SARS-CoV-2 Infections: Rapid Living Systematic Review and Meta-Analysis. medRxiv. 2020 May;p. 2020.04.25.20079103.

[53] Cohen R, Jung C, Ouldali N, Sellam A, Batard C, Cahn-Sellem F, et al. Assessment of Spread of SARS-CoV-2 by RT-PCR and Concomitant Serology in Children in a Region Heavily Affected by COVID-19 Pandemic. medRxiv. 2020 Jun;p. 2020.06.12.20129221.

[54] Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering How Biological Sex Impacts Immune Responses and COVID-19 Outcomes. Nature Reviews Immunology. 2020 Jun;p. 1–6.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

[55] Prem K, Cook AR, Jit M. Projecting Social Contact Matrices in 152 Countries Using Contact Surveys and Demographic Data. PLOS Computational Biology. 2017 Sep;13(9):e1005697.

[56] May RM, Anderson RM. Spatial Heterogeneity and the Design of Immunization Programs. Mathematical Biosciences. 1984 Nov;72(1):83–111.

[57] Fraser C, Riley S, Anderson RM, Ferguson NM. Factors That Make an Infectious Disease Outbreak Controllable. Proceedings of the National Academy of Sciences. 2004 Apr;101(16):6146–6151.



Figure S1: **Practicability of the age-structured optimal control.** (a)-(b) Step optimal controls with a 3-weeks update over the older and younger populations. The corresponding optimal is given by Figure 4b. (c)-(d) Cumulative deaths per age at final time $T = 365$ days.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure S2: **The effect of paucisymptomatic infections, through their proportion p, on the optimal control c^*.**

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

A The basic reproduction number

Here we compute the basic reproduction number R_0 of the model (3)-(5). First let us set for $i \geq 0$ and $a \in [0, a_{\max}]$ the following functions

$$\pi_s(a,i) = \exp\left(-i\mu_{nat}(a) - \int_0^i [\gamma_{dir}(a)\mathbf{1}_{[i_{sympt}, i^s_{\max}]}(\sigma) + h_s(a,\sigma)]\mathrm{d}\sigma\right),$$
$$\pi_m(a,i) = \exp\left(-i\mu_{nat}(a) - \int_0^i h_m(a,\sigma)\mathrm{d}\sigma\right),$$
$$\pi_p(a,i) = \exp\left(-i\mu_{nat}(a) - \int_0^i h_p(a,\sigma)\mathrm{d}\sigma\right),$$

that describe the survival probability of infected individuals (in the respective compartment), with age a, from their infection until the time since infection i, in case of no hospitalisation (*i.e.* $H \equiv 0$). We get the following Volterra formulation of the linearized system of (3)-(5):

$$I_s(t,a,i) = \begin{cases} I_{s,0}(a,i-t)\frac{\pi_s(a,i)}{\pi_s(a,i-t)}, & \text{for } t \in [0,i), \\ (1-p)q(a)\lambda_0(t-i,a)S_0(a)\pi_s(a,i), & \text{for } t \geq i, \end{cases} \tag{A.1}$$

$$I_m(t,a,i) = \begin{cases} I_{m,0}(a,i-t)\frac{\pi_m(a,i)}{\pi_m(a,i-t)}, & \text{for } t \in [0,i), \\ (1-p)(1-q(a))\lambda_0(t-i,a)S_0(a)\pi_m(a,i), & \text{for } t \geq i \end{cases} \tag{A.2}$$

and

$$I_p(t,a,i) = \begin{cases} I_{A,0}(a,i-t)\frac{\pi_p(a,i)}{\pi_p(a,i-t)}, & \text{for } t \in [0,i), \\ p\lambda_0(t-i,a)S_0(a)\pi_p(a,i), & \text{for } t \geq i \end{cases} \tag{A.3}$$

where $\lambda_0 = \lambda(\cdot,\cdot,0)$ is defined by

$$\lambda_0(t,a) = \int_0^{a_{\max}} K(a,a') \int_0^\infty \left(\beta_s(a',i)I_s(t,a',i) + \beta_m(a',i)I_m(t,a',i) + \beta_p(a',i)I_p(t,a',i)\right) \mathrm{d}i\, \mathrm{d}a', \tag{A.4}$$

where β_k, $k \in \{s,m,p\}$ are defined in Section 3.2. Let $I_N(t,a) = \lambda_0(t,a)S_0(a)$ be the density of newly infected of age a at time t, with $c \equiv 0$. Then (A.1)-(A.2)-(A.3) can be rewritten as the following Volterra formulation:

$$I_N(t,a) = S_0(a)\int_0^t \int_0^{a_{\max}} K(a,a')\omega(a',i)I_N(t-i,a')\mathrm{d}a'\, \mathrm{d}i + f(t,a),$$

where

$$\omega(a',i) = \beta_s(a',i)(1-p)q(a')\pi_s(a',i) + \beta_m(a',i)(1-p)(1-q(a'))\pi_m(a',i) + \beta_p(a',i)p\pi_p(a',i)$$

and $f(t,a)$ is the density of new infections produced by the initial population. Therefore, the basic reproduction number R_0 is the spectral radius, denoted by $r(U)$, of the next generation operator U defined on $L^1_+(0,a_{\max})$ by

$$U : L^1(0,a_{\max}) \ni v \longmapsto S_0(\cdot)\int_0^\infty \int_0^{a_{\max}} K(\cdot,a')\omega(a',i)v(a')\mathrm{d}a'\, \mathrm{d}i \in L^1(0,a_{\max})$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

As explained in Section 3.2, it is estimated in [11] that each average infectiousness β_k ($k \in \{s,m,p\}$) takes the form of a Weibull distribution $W(3,5.65)$ so that the mean and median are equal to 5.0 days while the standard deviation is 1.9 days. Based on this estimation, we assume that $\beta_k(a,i) = \alpha\overline{\beta}(i)\xi_k(i)$ where $\overline{\beta} \sim W(3,5.65)$ and α is a positive parameter to be determined. Consequently, it follows that α is given by

$$\alpha = \frac{R_0}{r\left(\overline{U}\right)}, \tag{A.5}$$

where $\overline{U}$ is the operator defined by

$$\overline{U} : L^1(0,a_{\max}) \ni v \longmapsto S_0(\cdot)\int_0^{\infty}\int_0^{a_{\max}} K(\cdot,a')\overline{\varpi}(a',i)v(a')\mathrm{d}a'\,\mathrm{d}i \in L^1(0,a_{\max})$$

with

$$\overline{\varpi}(a',i) = \overline{\beta}(i)\left[\xi_s(i)(1-p)q(a')\pi_s(a',i) + \xi_m(i)(1-p)(1-q(a'))\pi_m(a',i) + \xi_p(i)p\pi_p(a',i)\right].$$

We see that $\overline{U}$ can be rewritten as

$$\overline{U}v(a) = S_0(a)\int_0^{a_{\max}} K(a,a')\overline{\Omega}(a')v(a')\mathrm{d}a',\ \forall v \in L^1_+(0,a_{\max}) \quad \text{where} \quad \overline{\Omega}\left(a'\right) = \int_0^{\infty}\overline{\varpi}(a',i)\mathrm{d}i.$$

Now, in order to compute the spectral radius $r\left(\overline{U}\right)$, we first make the following assumptions:

Assumption A.1 *We suppose that:*

a) *functions $S_0, K, \overline{\Omega}$ are bounded and positive almost everywhere;*

b) *the function K is symmetric.*

We can note that the Assumption A.1 is satisfied when using the parameters stated in Table 1. Now, let S be the positive self-adjoint operator defined by

$$S : L^2(0,a_{\max}) \ni v \longmapsto \sqrt{S_0(\cdot)\overline{\Omega}(\cdot)}\int_0^{a_{\max}} K(\cdot,a')\sqrt{S_0(a')\overline{\Omega}(a')}v(a')\mathrm{d}a' \in L^2_+(0,a_{\max})$$

(by symmetry of K supposed in Assumption A.1). We can deduce the following

Proposition A.2 *The operators $\overline{U}$ and S are positive and compact, their spectra $\sigma(\overline{U})\setminus\{0\}$ and $\sigma(S)\setminus\{0\}$ are composed of isolated eigenvalues with finite algebraic multiplicity. Moreover, we have $\sigma(\overline{U}) = \sigma(S) \subset \mathbb{R}_+$ and the following Rayleigh formula holds:*

$$r(\overline{U}) = r(S) = \sup_{\substack{v\in L^2(0,a_{\max})\\ \|v\|_{L^2(0,a_{\max})}=1}} \int_0^{a_{\max}}\int_0^{a_{\max}} K(a,a')\sqrt{S_0(a')\overline{\Omega}(a')}\sqrt{S_0(a)\overline{\Omega}(a)}v(a')v(a)\mathrm{d}a'\,\mathrm{d}a.$$

Proof. The compactness of both integral operators follows from the fact that $a_{\max} < \infty$ by assumption (see Table 1), hence their spectra are punctual. Now we prove that $\sigma(\overline{U}) = \sigma(S)$. Let $\nu \in \sigma(\overline{U})$ be an eigenvalue of $\overline{U}$ and $\phi \in L^1(0,a_{\max})$ be the associated eigenvector, *i.e.*

$$\overline{U}\phi(a) = S_0(a)\int_0^{a_{\max}} K(a,a')\overline{\Omega}(a')\phi(a')\mathrm{d}a' = \nu\phi(a), \quad \forall a \in [0,a_{\max}]$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

so that $\phi \in L^\infty(0,a_{\max}) \subset L^2(0,a_{\max})$. Defining the function

$$\psi = \frac{\phi\sqrt{\overline{\Omega}}}{\sqrt{S_0}} \in L^2(0,a_{\max})$$

leads to

$$\nu\psi(a) = \sqrt{S_0(a)\overline{\Omega}(a)}\int_0^{a_{\max}} K(a,a')\sqrt{\overline{\Omega}(a')S_0(a')}\psi(a')\mathrm{d}a' = S\psi(a), \quad \forall a \in [0,a_{\max}]$$

i.e. $\nu \in \sigma(S)$ is an eigenvalue of S associated to the eigenvector ψ, so that $\sigma(\overline{U}) \subset \sigma(S)$. For the reverse inclusion, let $\nu \in \sigma(S)$ and $\psi \in L^2(0,a_{\max}) \subset L^1(0,a_{\max})$ be the associated eigenvector for S. It follows that the function

$$\phi = \frac{\psi\sqrt{S_0}}{\sqrt{\overline{\Omega}}} \in L^1(0,a_{\max})$$

is an eigenvector of $\overline{U}$ related to the eigenvalue $\nu \in \sigma(\overline{U})$, whence $\sigma(\overline{U}) = \sigma(S)$. In particular, both spectral radius are equal. Finally, the Rayleigh formula is classical for positive and symmetric operators. ■

Remark A.3 *Numerically, to compute $r(\overline{U})$, we can similarly show that it is given by the spectral radius of the following operator:*

$$L^1(0,a_{\max}) \ni v \longmapsto \int_0^{a_{\max}} K(\cdot,a')\overline{\Omega}(a')S_0(a')v(a')\mathrm{d}a' \in L^1(0,a_{\max})$$

which can be easily computed since the age a is numerically divided into 20 classes, so that the term inside the integral of the latter equation is a 20×20 matrix. Finally, we obtain α from (A.5).

B Computations of the adjoint system

In order to deal with the necessary optimality conditions, we use some results in [46]. Next, we detail the computations of the adjoint system (12)-(13). To this end, we first define the functions $y_1, Q : [0,T]\times[0,a_{\max}] \to \mathbb{R}$ and $y_2 : [0,T]\times[0,a_{\max}]\times\mathbb{R}_+$ by:

$$y_1(t,a) = \begin{pmatrix} S(t,a) \\ R(t,a) \end{pmatrix} \quad y_2(t,a,i) = \begin{pmatrix} I_s(t,a,i) \\ I_m(t,a,i) \\ I_p(t,a,i) \end{pmatrix}, \quad Q(t,a) = \begin{pmatrix} H(t) & E(t,a) & b(t,a) \end{pmatrix}$$

wherein

$$g_H(i,y_2(t,a,i)) = I_s(t,a,i)1_{[i_{sympt},\infty)}(i), \qquad g_R(i,y_2(t,a,i)) = \sum_{k\in\{s,m,p\}} h_k(a,i)I_k(t,a,i),$$

$$g_\lambda(a,i,y_1,y_2) = S(t,a)\int_0^{a_{\max}} K(a,a')\left(\beta_s(a',i)I_s(t,a',i) + \beta_m(a',i)I_m(t,a',i) + \beta_p(a',i)I_p(t,a',i)\right)\mathrm{d}a',$$

$$H(t) = \int_0^\infty\int_0^{a_{\max}} g_H(i,y_2(t,a,i))\mathrm{d}a\,\mathrm{d}i, \qquad E(t,a) = \int_0^\infty g_\lambda(a,i,y_1(t,a,i),y_2(t,a,i))\mathrm{d}i,$$

$$b(t,a) = \int_0^\infty g_R(i,y_2(t,a,i))\mathrm{d}i.$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

The model (5) thus rewrites as

$$\begin{cases} \partial_t y_1(t,a) &= F_1(a,Q(t,a),c(t,a),y_1(t,a)), \\ (\partial_t+\partial_i)\, y_2(t,a,i) &= F_2(a,i,Q(t,a),c(t,a),y_2(t,a,i)), \\ y_2(t,a,0) &= \Phi(a,c(t,a),E(t,a)), \end{cases}$$

with

$$F_1(a,Q(t,a),c(t,a),y_1(t,a)) = \begin{pmatrix} -\mu(a,H(t))S(t,a)-(1-c(t,a))E(t,a) \\ -\mu(a,H(t))R(t,a)+b(t,a) \end{pmatrix},$$

$$F_2(a,i,Q(t,a),c(t,a),y_2(t,a,i)) = \begin{pmatrix} -(\mu(a,H(t))+\gamma(a,i,H(t))+h_s(a,i))I_s(t,a,i) \\ -(\mu(a,H(t))+h_m(a,i))I_m(t,a,i) \\ -(\mu(a,H(t))+h_p(a,i))I_p(t,a,i) \end{pmatrix}$$

and

$$\Phi(a,c(t,a),Q(t,a)) = \begin{pmatrix} (1-p)q(a)(1-c(t,a))E(t,a) \\ (1-p)(1-q(a))(1-c(t,a))E(t,a) \\ p(1-c(t,a))E(t,a) \end{pmatrix}.$$

We now rewrite the functional J as

$$J(c) = \int_0^T \int_0^{a_{\max}} \left(\mathscr{J}_1(a,c(t,a),Q(t,a),y_1(t,a)) + \int_0^\infty \mathscr{J}_2(a,i,Q(t,a),y_2(t,a,i))\mathrm{d}i \right) \mathrm{d}a\, \mathrm{d}t$$

which is decomposed into

$$\mathscr{J}_1(a,c(t,a),Q(t,a),y_1(t,a)) = \mu_{add}(a,H(t))(S(t,a)+R(t,a))+B(a)c^2(t,a)$$

and

$$\mathscr{J}_2(a,i,Q(t,a),y_2(t,a,i)) = \gamma(a,i,H(t))I_s(t,a,i)+\mu_{add}(a,H(t))(I_s(t,a,i)+I_m(t,a,i)+I_p(t,a,i)).$$

We denote by $z_1, \zeta_k : [0,T]\times[0,a_{\max}] \to \mathbb{R}$ (for $k\in\{1,2,3\}$) the following adjoint functions

$$z_1(t,a) = (z_S(t,a), z_R(t,a)), \quad \zeta(t,a) = (\zeta_1(t,a), \zeta_2(t,a), \zeta_3(t,a)),$$

and we denote by $z_2 : [0,T]\times[0,a_{\max}]\times\mathbb{R}_+$ the following adjoint function

$$z_2(t,a,i) = (z_{I_s}(t,a,i), z_{I_m}(t,a,i), z_{I_p}(t,a,i)),$$

satisfying $\lim_{i\to\infty} z_2(t,a,i) = 0$ and $z_1(T,a) = z_2(T,a,i) = 0$. We get

$$\nabla_{y_1}\mathscr{J}_1(a,c(t,a),Q(t,a),y_1(t,a)) = \begin{pmatrix} \mu_{add}(a,H(t)) \\ \mu_{add}(a,H(t)) \end{pmatrix}^T$$

$$\nabla_{y_2}\mathscr{J}_2(a,i,Q(t,a),y_2(t,a,i)) = \begin{pmatrix} \mu_{add}(a,H(t))+\gamma(a,i,H(t)) \\ \mu_{add}(a,H(t)) \\ \mu_{add}(a,H(t)) \end{pmatrix}^T$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

$$\nabla_{y_1} F_1(a, Q(t,a), c(t,a), y_1(t,a)) = \begin{pmatrix} -\mu(a,H(t)) & 0 \\ 0 & -\mu(a,H(t)) \end{pmatrix}$$

and

$$\nabla_{y_2} F_2 = \begin{pmatrix} -\mu(a,H(t)) - \gamma(a,i,H(t)) - h_s(a,i) & 0 & 0 \\ 0 & -\mu(a,H(t)) - h_m(a,i) & 0 \\ 0 & 0 & -\mu(a,H(t)) - h_p(a,i) \end{pmatrix}.$$

Then

$$(z_1 \cdot \nabla_{y_1} F_1)(t,a) = \begin{pmatrix} -\mu(a,H(t)) z_S(t,a) & -\mu(a,H(t)) z_R(t,a) \end{pmatrix}$$

and

$$(z_2 \cdot \nabla_{y_2} F_2)(t,a,i) = \begin{pmatrix} -(\mu+\gamma+h_s) z_{I_s}(t,a,i) & -(\mu+h_m) z_{I_m}(t,a,i) & -(\mu+h_p) z_{I_p}(t,a,i) \end{pmatrix}.$$

Setting

$$g_1(a,y_1,y_2) = \begin{pmatrix} \int_0^\infty g_H(i, y_2(t,a,i)) \mathrm{d}i \\ E(t,a) \\ b(t,a) \end{pmatrix}, \quad g_2(a,i,y_1,y_2) = \begin{pmatrix} g_H(i, y_2(t,a,i)) \\ g_\lambda(a,i,y_1(t,a,i), y_2(t,a,i)) \\ g_R(i, y_2(t,a,i)) \end{pmatrix},$$

we see that

$$\nabla_{y_1} g_1(a,y_1,y_2) = \begin{pmatrix} 0 & 0 \\ \int_0^\infty \int_0^{a_{\max}} K(a,a')(\beta_s(a',i) I_s(t,a',i) + \beta_m(a',i) I_m(t,a',i) + \beta_p(a',i) I_p(t,a',i)) \mathrm{d}a' \, \mathrm{d}i & 0 \\ 0 & 0 \end{pmatrix}$$

and

$$\nabla_{y_2} g_2(a,i,y_1,y_2) = \begin{pmatrix} \mathbf{1}_{[i_{sympt},\infty)}(i) & 0 & 0 \\ S(t,\cdot)\beta_s(a,i) K(\cdot,a) & S(t,\cdot)\beta_m(a,i) K(\cdot,a) & S(t,\cdot)\beta_p(a,i) K(\cdot,a) \\ h_s(a,i) & h_m(a,i) & h_p(a,i) \end{pmatrix}.$$

From there, we deduce that

$$(\zeta \cdot \nabla_{y_1} g_1)(t,a) = \begin{pmatrix} \zeta_2(t,a) \int_0^\infty \int_0^{a_{\max}} K(a,a')(\beta_s(a',i) I_s(t,a',i) + \beta_m(a',i) I_m(t,a',i) + \beta_p(a',i) I_p(t,a',i)) \mathrm{d}a' \mathrm{d}i & 0 \end{pmatrix}$$

and

$$(\zeta \cdot \nabla_{y_2} g_2)(t,a,i) = \begin{pmatrix} \zeta_1(t,a) \mathbf{1}_{[i_{sympt},\infty)}(i) + \beta_s(a,i) \int_0^{a_{\max}} \zeta_2(t,a') S(t,a') K(a',a) \mathrm{d}a' + \zeta_3(t,a) h_s(a,i) \\ \beta_m(a,i) \int_0^{a_{\max}} \zeta_2(t,a') S(t,a') K(a',a) \mathrm{d}a' + \zeta_3(t,a) h_m(a,i) \\ \beta_p(a,i) \int_0^{a_{\max}} \zeta_2(t,a') S(t,a') K(a',a) \mathrm{d}a' + \zeta_3(t,a) h_p(a,i) \end{pmatrix}^T.$$

The adjoint system is given by

$$\begin{cases} -\frac{\partial z_1}{\partial t}(t,a) &= \nabla_{y_1} \mathscr{J}_1(t,a) + (z_1 \cdot \nabla_{y_1} F_1)(t,a) + (\zeta \cdot \nabla_{y_1} g_1)(t,a) \\ -(\frac{\partial z_2}{\partial t} + \frac{\partial z_2}{\partial i})(t,a,i) &= \nabla_{y_2} \mathscr{J}_2(t,a) + (z_2 \cdot \nabla_{y_2} F_2)(t,a,i) + (\zeta \cdot \nabla_{y_2} g_2)(t,a,i) \end{cases}$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.23.20138099; this version posted August 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

which is equivalent to (12). Next, we see that

$$\nabla_Q \Phi(t,a) = \begin{pmatrix} 0 & (1-p)q(a)(1-c(t,a)) & 0 \\ 0 & (1-p)(1-q(a))(1-c(t,a)) & 0 \\ 0 & p(1-c(t,a)) & 0 \end{pmatrix}$$

whence

$$(z_2(\cdot,\cdot,0)\cdot\nabla_Q\Phi)(t,a) = \begin{pmatrix} 0 & [1-c(t,a)][(1-p)(q(a)z_{I_s}+(1-q(a))z_{I_m})+pz_{I_p}](t,a,0) & 0 \end{pmatrix}.$$

Further, we have

$$\nabla_Q \mathscr{J}_1(t,a) = \begin{pmatrix} \frac{\partial\mu}{\partial H}(a,H(t))(S(t,a)+R(t,a)) & 0 & 0 \end{pmatrix}$$

and

$$\nabla_Q \mathscr{J}_2(t,a,i) = \begin{pmatrix} \frac{\partial\mu}{\partial H}(a,H(t))(I_s(t,a,i)+I_m(t,a,i)+I_p(t,a,i)) + \frac{\partial\gamma}{\partial H}(a,i,H(t))I_s(t,a,i) & 0 & 0 \end{pmatrix}.$$

We also see that $\nabla_Q g_1 \equiv 0$, $\nabla_Q g_2 \equiv 0$,

$$\nabla_Q F_1(t,a) = \begin{pmatrix} -\frac{\partial\mu}{\partial H}(a,H(t))S(t,a) & -(1-c(t,a)) & 0 \\ -\frac{\partial\mu}{\partial H}(a,H(t))R(t,a) & 0 & 1 \end{pmatrix}$$

and

$$\nabla_Q F_2(t,a,i) = \begin{pmatrix} -\left(\frac{\partial\mu}{\partial H}(a,H(t))+\frac{\partial\gamma}{\partial H}(a,i,H(t))\right)I_s(t,a,i) & 0 & 0 \\ -\frac{\partial\mu}{\partial H}(a,H(t))I_m(t,a,i) & 0 & 0 \\ -\frac{\partial\mu}{\partial H}(a,H(t))I_p(t,a,i) & 0 & 0 \end{pmatrix}$$

whence

$$(z_1\cdot\nabla_Q F_1)(t,a) = \begin{pmatrix} -\frac{\partial\mu}{\partial H}(a,H(t))S(t,a)z_S(t,a) - \frac{\partial\mu}{\partial H}(a,H(t))R(t,a)z_R(t,a) \\ -(1-c(t,a))z_S(t,a) \\ z_R(t,a) \end{pmatrix}^T$$

and

$$(z_2\cdot\nabla_Q F_2)(t,a,i) = \begin{pmatrix} -\left(\frac{\partial\mu}{\partial H}+\frac{\partial\gamma}{\partial H}\right)I_s z_{I_s} - \frac{\partial\mu}{\partial H}I_m z_{I_m} - \frac{\partial\mu}{\partial H}I_p z_{I_p} & 0 & 0 \end{pmatrix}.$$

Finally, the adjoint functions ζ must satisfy the following equation:

$$\begin{aligned}\zeta(t,a) =& (z_2(\cdot,\cdot,0)\cdot\nabla_Q\Phi)(t,a) + (\nabla_Q\mathscr{J}_1(t,a)) + (z_1\cdot\nabla_Q F_1)(t,a) + (\zeta\cdot\nabla_Q g_1)(t,a) \\ &+ \int_0^\infty (\nabla_Q\mathscr{J}_2(t,a,i) + (z_2\cdot\nabla_Q F_2)(t,a,i) + (\zeta\cdot\nabla_Q g_2)(t,a,i))\,\mathrm{d}i\end{aligned}$$

which is equivalent to (13). Finally, the Hamiltonian is given by

$$\mathscr{H}(t,a,c) = z_2(t,a,0)\cdot\Phi(t,a,c,Q) + \mathscr{J}_1(a,c,Q,y_1) + \int_0^\infty \mathscr{J}_2(a,i,Q,y_2)\mathrm{d}i$$

which leads to

$$\begin{aligned}\mathscr{H}(t,a,c) =& E(t,a)[1-c(t,a)][(1-p)(q(a)z_{I_s}+(1-q(a))z_{I_m})+pz_{I_p}](t,a,0) \\ &+ \mu_{add}(a,H(t))(S(t,a)+R(t,a)) + B(a)c^2(t,a) \\ &+ \int_0^\infty (\gamma(a,i,H(t))I_s(t,a,i) + \mu_{add}(a,H(t))(I_s(t,a,i)+I_m(t,a,i)+I_p(t,a,i)))\,\mathrm{d}i. \qquad \text{(B.1)}\end{aligned}$$